Baxdrostat
Chemical compound
- 1 min read
- 4 chapters
Related on Lably
Through Medication
Baxdrostat was approved for medical use in the United States in May 2026.
Medical uses
Baxdrostat is indicated for the treatment of hypertension in combination with other antihypertensive drugs, to lower blood pressure in adults who are not adequately controlled on other agents.
Sign in to keep reading
3 more chapters are free with a Lably account.
Mechanism of action
Aldosterone dysregulation contributes significantly to the pathogenesis of resistant hypertension. While conventional drugs act by blocking the mineralocorticoid receptor, baxdrostat, an aldosterone synthase inhibitor, targets the aldosterone synthesis directly.
History
Clinical trials
BrigHTN
In adults with treatment-resistant hypertension, treatment with baxdrostat at doses of 1 mg or 2 mg daily produced significantly greater reductions in systolic blood pressure over 12 weeks compared to placebo.
BaxHTN
BaxHTN is a phase III trial. It found that adding once-daily baxdrostat to standard antihypertensive therapy led to significantly greater reductions in seated systolic blood pressure at 12 weeks compared with placebo, in adults with uncontrolled or resistant hypertension.
Bax24
Treatment with a once-daily 2mg dose of baxdrostat resulted in a clinically significant reduction in ambulatory systolic blood pressure reading over 12 weeks compared to placebo. A side effect of hyperkalaemia was noted.
Society and culture
Legal status
Baxdrostat was approved for medical use in the United States in May 2026.
Names
Baxdrostat is the international nonproprietary name.
Baxdrostat is sold under the brand name Baxfendy.